As the 2023 RSV season begins to accelerate in the United States, pregnant women have two options to protect their child from the Respiratory Syncytial Virus (RSV).
Over the past month, the U.S. Food and Drug Administration (FDA) approved an RSV monoclonal antibody (mAb) and vaccine to protect infants from RSV.
On August 21, 2023, the FDA approved the first vaccine for pregnant women to prevent lower respiratory tract disease (LRTD) and severe LRTD caused by RSV in infants from birth through 6 months.
Read More
